Stereotaxis Computed Tomography (CT) Co-Registration Study

March 8, 2011 updated by: Stereotaxis

Randomized Feasibility Study Comparing the Clinical Utility of the Stereotaxis Navigant™ Computed Tomography Angiography Importation and Co- Registration Feature, the NaviView™ Assisted Navigation Feature, and Standard Angiography

The Stereotaxis Niobe® II Magnetic Navigation System (MNS) is designed to direct and digitally control catheter and guidewire based therapeutic and diagnostic devices along complex trajectories within the heart and coronary vasculature.

Navigation using vectors acquired from the CT Co-registration feature of Navigant™ provides clinical benefits for percutaneous coronary intervention (PCI) by decreasing the amount of contrast used during complex PCI procedures.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

4

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10032
        • New York Presbyterian Hospital-Columbia Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients must be between 18-80 years of age
  • Willing and able to provide prior written informed consent
  • Patients present with a single bifurcated lesion or single non-CTO complex lesion requiring PCI.
  • Able to be safely exposed to magnetic fields, such as magnetic resonance imaging (MRI)
  • CT angiography performed prior to cardiac catheterization (must be performed >48 hours prior to procedure to limit peri-procedural contrast use, but <12 months prior to the procedure)

Exclusion Criteria:

  • Patients with a creatinine greater than 2.0 mg/dL
  • Exclude patients whom in the Investigator's opinion, are hemodynamically unstable on the day of the procedure.
  • Untreatable allergy to contrast media
  • Patients who have undergone CT angiography within 48 hours of index PCI procedure
  • Patients with chronic total occlusions (CTOs) requiring intervention.
  • Patients requiring treatment for lesions other than the single bifurcated or single non-CTO complex lesion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A-CT Coregistration
5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
Procedure: Percutaneous coronary intervention
non surgical procedure to open blocked coronary arteries
Active Comparator: Group B-Angiographic
5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
Procedure: Percutaneous coronary intervention
non surgical procedure to open blocked coronary arteries
Active Comparator: Group C-Standard Angiography
5 subjects with standard angiography in a conventional PCI (Group C)
Procedure: Percutaneous coronary intervention
non surgical procedure to open blocked coronary arteries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary endpoint is to compare and evaluate the total contrast use between Groups A, B and C .
Time Frame: 6 months
6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
The secondary endpoint is to compare and evaluate the following data points between Groups A, B and C: fluoroscopy time, procedure time, crossing time, procedural contrast use, adverse events (AEs): e.g. clinically significant perforations
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stereotaxis

Investigators

  • Principal Investigator: Jeffrey Moses, MD, New York Presbyterian Hospital-Columbia Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2009

Primary Completion (Actual)

March 1, 2011

Study Completion (Actual)

March 1, 2011

Study Registration Dates

First Submitted

October 9, 2009

First Submitted That Met QC Criteria

October 13, 2009

First Posted (Estimate)

October 14, 2009

Study Record Updates

Last Update Posted (Estimate)

March 10, 2011

Last Update Submitted That Met QC Criteria

March 8, 2011

Last Verified

March 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PM-CLIN-011

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Percutaneous coronary intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe